• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    6/17/24 4:31:09 PM ET
    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    Gainers

    • ASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million.
    • Biora Therapeutics (NASDAQ:BIOR) shares rose 11.64% to $0.75. The company's market cap stands at $26.9 million.
    • Qualigen Therapeutics (NASDAQ:QLGN) shares increased by 10.99% to $0.19. The market value of their outstanding shares is at $1.2 million.
    • CVRx (NASDAQ:CVRX) stock moved upwards by 9.48% to $12.0. The company's market cap stands at $259.1 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 8.68% to $0.27.
    • Fresh2 Group (NASDAQ:FRES) shares rose 7.56% to $0.34. The market value of their outstanding shares is at $8.3 million.

    Losers

    • Anitra (AMEX:AZTR) shares decreased by 21.3% to $0.18 during Monday's after-market session. The company's market cap stands at $5.3 million.
    • Mustang Bio (NASDAQ:MBIO) shares fell 15.98% to $0.63. The company's market cap stands at $17.7 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares declined by 14.39% to $0.12. The market value of their outstanding shares is at $2.0 million.
    • Nexalin Technology (NASDAQ:NXL) shares fell 9.2% to $0.69. The company's market cap stands at $5.0 million.
    • PAVmed (NASDAQ:PAVM) stock fell 8.92% to $0.92. The company's market cap stands at $8.6 million.
    • Tiziana Life Sciences (NASDAQ:TLSA) shares fell 8.8% to $0.72. The market value of their outstanding shares is at $73.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $AZTR
    $BIOR
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    CVRx Inc.
    $CVRX
    5/9/2025$7.00Neutral → Underweight
    Analyst
    CVRx Inc.
    $CVRX
    1/14/2025Mkt Perform → Outperform
    William Blair
    CVRx Inc.
    $CVRX
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    CVRx Inc.
    $CVRX
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    CVRx Inc.
    $CVRX
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    CVRx Inc.
    $CVRX
    5/1/2024Outperform → Mkt Perform
    William Blair
    CVRx Inc.
    $CVRX
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    CVRx Inc.
    $CVRX
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVRx, Inc. downgraded by Analyst with a new price target

    Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

    5/9/25 8:41:10 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx, Inc. upgraded by William Blair

    William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

    1/14/25 7:51:14 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

    Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

    9/10/24 7:46:21 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

    BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive preclinical data highlighting nasal anti-CD3's potential as a novel approach to address neuroinflammation associated with aging, which contributes to cognitive decline in age-related disorders. In the study, nasal anti-CD3 reversed key aspects of brain aging, and improved cognition. Key study findings: Nasal anti-CD3 dampens microglial activation that drives chronic neuroinflammation. This reduction in inflammation, which is strongly linked to cognitiv

    4/1/26 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives to maximize shareholder value. The Company intends to continue executing on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process.

    3/31/26 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    SEC Filings

    View All

    SEC Form 4 filed by Aklog Lishan

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 6:53:45 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Mcgrath Dennis M

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 4:51:51 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Glennon Michael J

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 4:50:30 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by China Pharma Holdings Inc.

    10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:15:23 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by China Pharma Holdings Inc.

    NT 10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:05:03 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Tiziana Life Sciences Ltd.

    6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

    4/1/26 7:00:01 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

    HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin's strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer's disease and Traumatic Brain Injury (TBI). In anticipation of the Company's new FDA submissions, Dr. Rothstein will support Nexalin's preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein bring

    10/13/25 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Financials

    Live finance-specific insights

    View All

    PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagno

    3/30/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $ASLN
    $AZTR
    $BIOR
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mustang Bio Inc.

    SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

    11/14/24 4:21:44 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care